Feline Calicivirus Vaccine

Abstract

Isolated Novel Feline Calicivirus hFCV for Detecting and Preventing Infection

Full Description

Feline calicivirus (FCV) is a common pathogen in multiple cat environments such as shelters and catteries. FCV infection can cause a variety of usually self-limiting signs including fever, upper respiratory signs, acute or chronic oral disease, limping, and occasionally pneumonia. Over the last decade, numerous outbreaks of a highly fatal hemorrhagic form of FCV infection have been observed worldwide. This form of FCV infection often comes from young shelter cats and spreads rapidly by indirect and direct contact to older well-vaccinated household pet cats. Laboratory studies have confirmed these hemorrhagic strains to be resistant to current FCV vaccines. The best way to protect feline populations against this highly fatal form of FCV infection is via vaccines that include a broader immunity.

Researchers at the University of California, Davis are proud to offer an invention relating to a vaccine against infections with hemorrhagic feline calicivirus (hFCV). This invention involves the incorporation of particular strains of hFCV into a new generation of vaccines.

This invention is available for licensing on a non-exclusive basis.

Suggested uses

The FCV vaccine can be used in accordance with routine vaccines as well as in vaccination clinics and veterinarian hospitals in order to fight certain viruses and protect against new as well as old strains.

Features/Benefits

• hFCV strains can be used in a new generation of vaccines to produce a much broader spectrum of immunity.
• More broadly reactive FCV vaccines, immunizing against both common and hemorrhagic strains of vaccine, will provide a new market opportunity.

Patent Status